KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

PURPOSE: VEGF pathway inhibitors have been investigated as therapeutic agents in the treatment of non–small cell lung cancer (NSCLC) because of its central role in angiogenesis. These agents have improved survival in patients with advanced NSCLC, but the effects have been modest. Although VEGFR2/KDR...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Nilsson, Monique B., Giri, Uma, Gudikote, Jayanthi, Tang, Ximing, Lu, Wei, Tran, Hai, Fan, Youhong, Koo, Andrew, Diao, Lixia, Tong, Pan, Wang, Jing, Herbst, Roy, Johnson, Bruce E., Ryan, Andy, Webster, Alan, Rowe, Philip, Wistuba, Ignacio I., Heymach, John V.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4834253/
https://ncbi.nlm.nih.gov/pubmed/26578684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1994
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg